Copyright Reports & Markets. All rights reserved.

Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Research Report 2021

Request for Sample of this report
Buy now

1 Vascular Endothelial Growth Factor (VEGF) Antibodies Market Overview

  • 1.1 Product Overview and Scope of Vascular Endothelial Growth Factor (VEGF) Antibodies
  • 1.2 Vascular Endothelial Growth Factor (VEGF) Antibodies Segment by Type
    • 1.2.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Growth Rate Comparison by Type (2021-2027)
    • 1.2.2 Bevacizumab
    • 1.2.3 Ranibizumab
    • 1.2.4 Aflibercept
    • 1.2.5 Others
  • 1.3 Vascular Endothelial Growth Factor (VEGF) Antibodies Segment by Application
    • 1.3.1 Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Comparison by Application: (2021-2027)
    • 1.3.2 Hospitals
    • 1.3.3 Specialty Clinics
    • 1.3.4 Ambulatory Surgical Centers
    • 1.3.5 Cancer Research Institutes
    • 1.3.6 Others
  • 1.4 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size Estimates and Forecasts
    • 1.4.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue 2016-2027
    • 1.4.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales 2016-2027
    • 1.4.3 Vascular Endothelial Growth Factor (VEGF) Antibodies Market Size by Region: 2016 Versus 2021 Versus 2027

2 Vascular Endothelial Growth Factor (VEGF) Antibodies Market Competition by Manufacturers

  • 2.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Manufacturers (2016-2021)
  • 2.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Manufacturers (2016-2021)
  • 2.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Average Price by Manufacturers (2016-2021)
  • 2.4 Manufacturers Vascular Endothelial Growth Factor (VEGF) Antibodies Manufacturing Sites, Area Served, Product Type
  • 2.5 Vascular Endothelial Growth Factor (VEGF) Antibodies Market Competitive Situation and Trends
    • 2.5.1 Vascular Endothelial Growth Factor (VEGF) Antibodies Market Concentration Rate
    • 2.5.2 The Global Top 5 and Top 10 Largest Vascular Endothelial Growth Factor (VEGF) Antibodies Players Market Share by Revenue
    • 2.5.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Vascular Endothelial Growth Factor (VEGF) Antibodies Retrospective Market Scenario by Region

  • 3.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Retrospective Market Scenario in Revenue by Region: 2016-2021
  • 3.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Retrospective Market Scenario in Sales by Region: 2016-2021
  • 3.3 North America Vascular Endothelial Growth Factor (VEGF) Antibodies Market Facts & Figures by Country
    • 3.3.1 North America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country
    • 3.3.2 North America Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country
    • 3.3.3 U.S.
    • 3.3.4 Canada
  • 3.4 Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Market Facts & Figures by Country
    • 3.4.1 Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country
    • 3.4.2 Europe Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country
    • 3.4.3 Germany
    • 3.4.4 France
    • 3.4.5 U.K.
    • 3.4.6 Italy
    • 3.4.7 Russia
  • 3.5 Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Market Facts & Figures by Region
    • 3.5.1 Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Region
    • 3.5.2 Asia Pacific Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Region
    • 3.5.3 China
    • 3.5.4 Japan
    • 3.5.5 South Korea
    • 3.5.6 India
    • 3.5.7 Australia
    • 3.5.8 Taiwan
    • 3.5.9 Indonesia
    • 3.5.10 Thailand
    • 3.5.11 Malaysia
    • 3.5.12 Philippines
    • 3.5.13 Vietnam
  • 3.6 Latin America Vascular Endothelial Growth Factor (VEGF) Antibodies Market Facts & Figures by Country
    • 3.6.1 Latin America Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country
    • 3.6.2 Latin America Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country
    • 3.6.3 Mexico
    • 3.6.4 Brazil
    • 3.6.5 Argentina
  • 3.7 Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Market Facts & Figures by Country
    • 3.7.1 Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Sales by Country
    • 3.7.2 Middle East and Africa Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue by Country
    • 3.7.3 Turkey
    • 3.7.4 Saudi Arabia
    • 3.7.5 UAE

4 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Historic Market Analysis by Type

  • 4.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Type (2016-2021)
  • 4.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Type (2016-2021)
  • 4.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Price by Type (2016-2021)

5 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Historic Market Analysis by Application

  • 5.1 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Sales Market Share by Application (2016-2021)
  • 5.2 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Revenue Market Share by Application (2016-2021)
  • 5.3 Global Vascular Endothelial Growth Factor (VEGF) Antibodies Price by Application (2016-2021)

6 Key Companies Profiled

  • 6.1 Roche
    • 6.1.1 Roche Corporation Information
    • 6.1.2 Roche Description and Business Overview
    • 6.1.3 Roche Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.1.4 Roche Product Portfolio
    • 6.1.5 Roche Recent Developments/Updates
  • 6.2 Novartis
    • 6.2.1 Novartis Corporation Information
    • 6.2.2 Novartis Description and Business Overview
    • 6.2.3 Novartis Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.2.4 Novartis Product Portfolio
    • 6.2.5 Novartis Recent Developments/Updates
  • 6.3 Sanofi
    • 6.3.1 Sanofi Corporation Information
    • 6.3.2 Sanofi Description and Business Overview
    • 6.3.3 Sanofi Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.3.4 Sanofi Product Portfolio
    • 6.3.5 Sanofi Recent Developments/Updates
  • 6.4 Regeneron
    • 6.4.1 Regeneron Corporation Information
    • 6.4.2 Regeneron Description and Business Overview
    • 6.4.3 Regeneron Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Regeneron Product Portfolio
    • 6.4.5 Regeneron Recent Developments/Updates
  • 6.5 Bayer
    • 6.5.1 Bayer Corporation Information
    • 6.5.2 Bayer Description and Business Overview
    • 6.5.3 Bayer Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.5.4 Bayer Product Portfolio
    • 6.5.5 Bayer Recent Developments/Updates
  • 6.6 AstraZeneca
    • 6.6.1 AstraZeneca Corporation Information
    • 6.6.2 AstraZeneca Description and Business Overview
    • 6.6.3 AstraZeneca Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.6.4 AstraZeneca Product Portfolio
    • 6.6.5 AstraZeneca Recent Developments/Updates
  • 6.7 Pfizer
    • 6.6.1 Pfizer Corporation Information
    • 6.6.2 Pfizer Description and Business Overview
    • 6.6.3 Pfizer Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.4.4 Pfizer Product Portfolio
    • 6.7.5 Pfizer Recent Developments/Updates
  • 6.8 Merck
    • 6.8.1 Merck Corporation Information
    • 6.8.2 Merck Description and Business Overview
    • 6.8.3 Merck Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.8.4 Merck Product Portfolio
    • 6.8.5 Merck Recent Developments/Updates
  • 6.9 Eli Lilly
    • 6.9.1 Eli Lilly Corporation Information
    • 6.9.2 Eli Lilly Description and Business Overview
    • 6.9.3 Eli Lilly Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.9.4 Eli Lilly Product Portfolio
    • 6.9.5 Eli Lilly Recent Developments/Updates
  • 6.10 GlaxoSmithKline
    • 6.10.1 GlaxoSmithKline Corporation Information
    • 6.10.2 GlaxoSmithKline Description and Business Overview
    • 6.10.3 GlaxoSmithKline Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.10.4 GlaxoSmithKline Product Portfolio
    • 6.10.5 GlaxoSmithKline Recent Developments/Updates
  • 6.11 Bristol-Myer Squibb
    • 6.11.1 Bristol-Myer Squibb Corporation Information
    • 6.11.2 Bristol-Myer Squibb Vascular Endothelial Growth Factor (VEGF) Antibodies Description and Business Overview
    • 6.11.3 Bristol-Myer Squibb Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.11.4 Bristol-Myer Squibb Product Portfolio
    • 6.11.5 Bristol-Myer Squibb Recent Developments/Updates
  • 6.12 Boehringer Ingelheim
    • 6.12.1 Boehringer Ingelheim Corporation Information
    • 6.12.2 Boehringer Ingelheim Vascular Endothelial Growth Factor (VEGF) Antibodies Description and Business Overview
    • 6.12.3 Boehringer Ingelheim Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.12.4 Boehringer Ingelheim Product Portfolio
    • 6.12.5 Boehringer Ingelheim Recent Developments/Updates
  • 6.13 Abcam Plc
    • 6.13.1 Abcam Plc Corporation Information
    • 6.13.2 Abcam Plc Vascular Endothelial Growth Factor (VEGF) Antibodies Description and Business Overview
    • 6.13.3 Abcam Plc Vascular Endothelial Growth Factor (VEGF) Antibodies Sales, Revenue and Gross Margin (2016-2021)
    • 6.13.4 Abcam Plc Product Portfolio
    • 6.13.5 Abcam Plc Recent Developments/Updates

7 Vascular Endothelial Growth Factor (VEGF) Antibodies Manufacturing Cost Analysis

  • 7.1 Vascular Endothelial Growth Factor (VEGF) Antibodies Key Raw Materials Analysis
    • 7.1.1 Key Raw Materials
    • 7.1.2 Key Suppliers of Raw Materials
  • 7.2 Proportion of Manufacturing Cost Structure
  • 7.3 Manufacturing Process Analysis of Vascular Endothelial Growth Factor (VEGF) Antibodies
  • 7.4 Vascular Endothelial Growth Factor (VEGF) Antibodies Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers

  • 8.1 Marketing Channel
  • 8.2 Vascular Endothelial Growth Factor (VEGF) Antibodies Distributors List
  • 8.3 Vascular Endothelial Growth Factor (VEGF) Antibodies Customers

9 Vascular Endothelial Growth Factor (VEGF) Antibodies Market Dynamics

  • 9.1 Vascular Endothelial Growth Factor (VEGF) Antibodies Industry Trends
  • 9.2 Vascular Endothelial Growth Factor (VEGF) Antibodies Growth Drivers
  • 9.3 Vascular Endothelial Growth Factor (VEGF) Antibodies Market Challenges
  • 9.4 Vascular Endothelial Growth Factor (VEGF) Antibodies Market Restraints

10 Global Market Forecast

  • 10.1 Vascular Endothelial Growth Factor (VEGF) Antibodies Market Estimates and Projections by Type
    • 10.1.1 Global Forecasted Sales of Vascular Endothelial Growth Factor (VEGF) Antibodies by Type (2022-2027)
    • 10.1.2 Global Forecasted Revenue of Vascular Endothelial Growth Factor (VEGF) Antibodies by Type (2022-2027)
  • 10.2 Vascular Endothelial Growth Factor (VEGF) Antibodies Market Estimates and Projections by Application
    • 10.2.1 Global Forecasted Sales of Vascular Endothelial Growth Factor (VEGF) Antibodies by Application (2022-2027)
    • 10.2.2 Global Forecasted Revenue of Vascular Endothelial Growth Factor (VEGF) Antibodies by Application (2022-2027)
  • 10.3 Vascular Endothelial Growth Factor (VEGF) Antibodies Market Estimates and Projections by Region
    • 10.3.1 Global Forecasted Sales of Vascular Endothelial Growth Factor (VEGF) Antibodies by Region (2022-2027)
    • 10.3.2 Global Forecasted Revenue of Vascular Endothelial Growth Factor (VEGF) Antibodies by Region (2022-2027)

11 Research Finding and Conclusion

    12 Methodology and Data Source

    • 12.1 Methodology/Research Approach
      • 12.1.1 Research Programs/Design
      • 12.1.2 Market Size Estimation
      • 12.1.3 Market Breakdown and Data Triangulation
    • 12.2 Data Source
      • 12.2.1 Secondary Sources
      • 12.2.2 Primary Sources
    • 12.3 Author List

    The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

    Segment by Type
    Bevacizumab
    Ranibizumab
    Aflibercept
    Others

    Segment by Application
    Hospitals
    Specialty Clinics
    Ambulatory Surgical Centers
    Cancer Research Institutes
    Others

    By Region
    North America
    U.S.
    Canada
    Europe
    Germany
    France
    U.K.
    Italy
    Russia
    Asia-Pacific
    China
    Japan
    South Korea
    India
    Australia
    Taiwan
    Indonesia
    Thailand
    Malaysia
    Philippines
    Vietnam
    Latin America
    Mexico
    Brazil
    Argentina
    Middle East & Africa
    Turkey
    Saudi Arabia
    UAE

    By Company
    Roche
    Novartis
    Sanofi
    Regeneron
    Bayer
    AstraZeneca
    Pfizer
    Merck
    Eli Lilly
    GlaxoSmithKline
    Bristol-Myer Squibb
    Boehringer Ingelheim
    Abcam Plc

    Buy now